A major analysis of 24 clinical trials involving 1,442 patients reveals that certain immunoadsorption treatments may offer real advantages for people with severe lupus nephritis, a kidney complication that affects 40 to 60 percent of lupus patients. The findings could help doctors choose the most effective treatment strategy for this serious autoimmune condition. What Is Lupus Nephritis and Why Does It Matter? Lupus nephritis (LN) occurs when systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues, damages the kidneys. In severe cases, patients develop high levels of protein in urine (3.5 grams or more in 24 hours), elevated creatinine levels (above 1.5 mg/dL, which indicates reduced kidney function), and active particles in urine. Without effective treatment, approximately 25 percent of lupus patients progress to end-stage renal disease, requiring dialysis or transplant. The condition is significantly more common in Asian populations than in European and American populations, suggesting genetic and environmental factors play a role. How Do These New Treatments Work Differently From Standard Care? Immunoadsorption (IA) is a specialized filtering technique that selectively removes harmful autoantibodies and immune complexes from the blood. Unlike traditional plasma exchange, which removes both harmful and beneficial proteins, immunoadsorption preserves the body's protective proteins while targeting only the problematic ones. This approach reduces inflammation and blocks the immune cascade that damages kidney tissue. Researchers from Liaoning University of Traditional Chinese Medicine and China Medical University conducted a systematic review and Bayesian network meta-analysis, comparing six different immunoadsorption columns used in clinical practice. Which Treatment Showed the Best Results? The analysis examined six immunoadsorption columns most commonly used for lupus nephritis treatment. DNA280 combined with standard medications showed favorable results for improving disease activity scores. When DNA280 was combined with plasma exchange and conventional therapy, it demonstrated a statistically significant advantage over standard treatment alone for reducing 24-hour protein loss in urine, with an improvement of 1.8 grams. PH-350 showed particular promise for improving serum creatinine levels, a key marker of kidney function. The research team analyzed outcomes across multiple kidney-related measures, including disease activity scores, protein levels, and immune markers. The findings suggest that DNA280-based regimens may offer relative advantages for severe lupus nephritis, though researchers emphasized that higher-quality comparative trials are still needed to confirm these results in real-world practice. Steps to Understanding Your Lupus Nephritis Treatment Options - Disease Activity Assessment: Ask your doctor to measure your SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) score, which tracks how active your lupus is and helps determine if your current treatment is working effectively. - Kidney Function Monitoring: Request regular tests of your serum creatinine levels and 24-hour urine protein measurements to track how well your kidneys are functioning and whether your treatment is protecting them. - Treatment Discussion: Talk with your rheumatologist about whether immunoadsorption therapy might be appropriate for you, and specifically ask about DNA280 or PH-350 options if standard medications aren't controlling your kidney disease. - Adverse Event Tracking: Keep detailed records of any side effects from your treatment, since the research showed that safety data across different immunoadsorption columns remains inconsistent and needs better documentation. What Are the Limitations of This Research? While the findings are encouraging, researchers acknowledged several important limitations. The quality of included studies varied, and some immunoadsorption columns had sparse comparative data. Additionally, adverse events were reported inconsistently across studies, making it difficult to compare safety profiles directly. The analysis relied on surrogate outcomes like protein levels rather than long-term kidney survival data. Researchers emphasized that these findings should be viewed as hypothesis-generating rather than definitive proof, and that larger, higher-quality trials comparing these treatments head-to-head are needed. The current standard treatment for severe lupus nephritis typically involves glucocorticoids combined with either cyclophosphamide or mycophenolate mofetil. However, some patients develop treatment resistance or experience cumulative drug toxicity, creating an urgent clinical need for additional therapeutic options. Immunoadsorption therapy represents a promising adjunctive approach that could help preserve kidney function in these difficult-to-treat cases. For patients living with lupus nephritis, these findings offer hope that more targeted, personalized treatment strategies may soon be available. If you have lupus with kidney involvement, discussing immunoadsorption therapy with your rheumatologist could be an important conversation, particularly if standard treatments aren't adequately controlling your disease activity or protecting your kidney function.
